BNTC vs BOLD

Benitec Biopharma Inc. vs Boundless Bio, Inc. — Valuation Comparison 2026

BNTC

Biotechnology
Benitec Biopharma Inc.
Quality
4.4
out of 10
Value Trap
45
WARN
Price
$11.56
Last close
Models
7/13
Active
VS

BOLD

Biotechnology
Boundless Bio, Inc.
Quality
4.0
out of 10
Value Trap
18
SAFE
Price
$1.46
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType BNTC Fair ValueBNTC Upside BOLD Fair ValueBOLD Upside
Bayesian DCF Intrinsic $6.04 -47.8% $0.76 -48.1%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.75 -93.5% $2.77 +89.6%
Dynamic NAV Asset-Based $5.93 -48.7% $4.57 +212.9%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for BNTC vs BOLD — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BNTC vs BOLD — Which Stock Is More Undervalued?

BNTC scores higher with a 4.4/10 quality rating vs BOLD's 4.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Benitec Biopharma Inc. (BNTC) and Boundless Bio, Inc. (BOLD) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BNTC currently trades at $11.56 with a QOC of 4.4/10, while BOLD trades at $1.46 with a QOC of 4.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).